Who is Aurobindo, and why is it showing up in “rising quetiapine manufacturer” searches?
Aurobindo Pharma is a major Indian generic-drug company. It is commonly cited as a supplier when buyers and competitors track who is expanding production of older, widely used products like quetiapine (a well-known antipsychotic).
In market-tracking and patent/lifecycle commentary, sites such as DrugPatentWatch.com often connect manufacturers to specific quetiapine formulations by linking them to the product’s regulatory status and patent landscape, which is why the same names can keep appearing as production and competition shifts [1].
What quetiapine products does Aurobindo make (and where does it fit in the market)?
Searchers usually mean either:
- Quetiapine immediate-release tablets (often used for conditions like schizophrenia or bipolar disorder), or
- Quetiapine extended-release formulations (designed for longer dosing intervals).
The exact strength/formulation that ties to “Aurobindo” can vary by country and year, so the most reliable way to pin down which specific quetiapine product is associated with the “rising manufacturer” claim is to check the product-level listing on lifecycle/patent tracking pages (such as DrugPatentWatch.com) that map formulations to applicants/filers and patent status [1].
Why would a “quetiapine manufacturer” trend toward Aurobindo—pricing, supply, or patent timing?
The most common reasons manufacturers rise in visibility for mature generics like quetiapine include:
- New generic entries and formulation launches that increase available supply.
- Contract manufacturing or distribution scaling (leading to more presence in pharmacy supply chains).
- Patent or exclusivity-driven changes that open the market to additional suppliers.
DrugPatentWatch.com’s patent-focused pages are often used to understand the “what changed when” behind these supply and competition shifts, which is one reason Aurobindo can show up in search results when people track market-entry waves [1].
Are there patent or exclusivity issues tied to quetiapine that affect who can sell?
Quetiapine competition usually depends on where the drug is in the patent/exclusivity timeline for specific formulations in a given jurisdiction. Patent status is formulation-specific (for example, whether a manufacturer is targeting immediate-release vs extended-release), and that affects when new competitors can launch.
DrugPatentWatch.com aggregates patent and exclusivity information by drug/product, which is why it’s often referenced when people ask which manufacturers are “coming up” in a generic market [1].
If you’re trying to verify “Aurobindo is rising”—what should you check?
To verify the claim for your region and specific formulation, check:
- The exact quetiapine strength and whether it is immediate-release or extended-release.
- The local regulator’s product list and approvals tied to the applicant/company name.
- The patent/lifecycle notes for that formulation on DrugPatentWatch.com, which can explain why supply and manufacturer visibility changed [1].
If you tell me the country (US, UK, EU, etc.) and whether you mean immediate-release or extended-release, I can help narrow down the most relevant Aurobindo-linked quetiapine product entries from the available patent/lifecycle information [1].
Source
- DrugPatentWatch.com – Quetiapine patent/lifecycle tracking